ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	9.53	4.36	2.38	9.45	1.93
Revenue Growth (YoY)	118.51%	83.31%	-74.84%	388.98%	-66.45%
Gross Profit	9.53	4.36	2.38	9.45	1.93
Selling, General & Admin	16.24	18.65	17.37	13.69	12.89
Research & Development	25.15	50.87	42.22	38.14	46.49
Operating Expenses	41.38	69.52	59.59	51.82	59.38
Operating Income	-31.86	-65.16	-57.21	-42.37	-57.45
Interest Expense / Income	1.46	5.13	3.41	4.03	1.08
Other Expense / Income	-5.12	-5.96	0.01	0.04	-2.18
Pretax Income	-28.2	-64.33	-60.62	-46.44	-56.35
Income Tax	-0.08	0.1	0.12	0.12	0.13
Net Income	-28.12	-64.42	-60.74	-46.57	-56.48
Shares Outstanding (Basic)	81	72	64	50	41
Shares Outstanding (Diluted)	81	72	64	50	41
Shares Change	13.08%	11.62%	28.21%	21.99%	20.51%
EPS (Basic)	-0.35	-0.90	-0.95	-0.93	-1.38
EPS (Diluted)	-0.35	-0.90	-0.95	-0.93	-1.38
Free Cash Flow	28.18	-69.21	-26.44	-47	-45.17
Free Cash Flow Per Share	0.35	-0.97	-0.41	-0.94	-1.10
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-334.48%	-1494.82%	-2405.80%	-448.24%	-2971.81%
Profit Margin	-295.21%	-1477.95%	-2554.25%	-492.65%	-2921.88%
Free Cash Flow Margin	295.82%	-1587.75%	-1111.73%	-497.21%	-2336.83%
EBITDA	-24.23	-56.68	-54.89	-40.06	-53.21
EBITDA Margin	-254.34%	-1300.30%	-2308.20%	-423.79%	-2752.87%
Depreciation & Amortization	2.51	2.52	2.33	2.36	2.05
EBIT	-26.74	-59.2	-57.22	-42.41	-55.27
EBIT Margin	-280.72%	-1358.13%	-2406.14%	-448.71%	-2859.03%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).